Home / What are peptides
What are peptides?
Short chains of amino acids. Some are well-tested prescription drugs; many sold online have never been through a human trial.
Why most peptides are injected
Digestion breaks peptides down the same way it breaks down protein in food, so most peptide drugs are given as a shot under the skin. There are exceptions: oral semaglutide (Rybelsus) uses an absorption enhancer, and orforglipron (Foundayo) is a small-molecule pill rather than a peptide. Powdered peptides have to be mixed with water first; the reconstitution calculator turns that into syringe units.
Approved, in trials, or neither
This is the question that matters most. Status as of 2026-11-16:
FDA-approved peptide drugs
Reviewed by the FDA for safety and effectiveness, with a label and a set dose.
Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
SemaglutideWeekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
Orforglipron (Foundayo)Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
TesamorelinGHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
Elamipretide (SS-31)Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.
Bremelanotide (PT-141)Melanocortin agonist (Vyleesi) approved for low sexual desire in premenopausal women. 1.75 mg as needed.
In clinical trials
Tested in human trials but not approved yet. Not legally sold for human use.
Weekly GIP, GLP-1 and glucagon agonist from Lilly. Phase 3, not approved; up to 28% weight loss in trials.
Cagrilintide (CagriSema)Long-acting amylin analogue from Novo Nordisk, paired with semaglutide as CagriSema. Not approved yet.
Not approved (sold as research chemicals)
Little or no controlled human data and no established dose.
The first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.
BPC-15715-amino-acid peptide studied mostly in animals. Not approved; no established human dose.
TB-500 (thymosin beta-4)Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.
GHK-Cu (copper peptide)Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.
KLOW and GLOW blendsSeller-defined mixes of GHK-Cu, BPC-157, TB-500 (GLOW) plus KPV (KLOW). No human data for any blend.
MOTS-c16-amino-acid mitochondrial peptide studied in animals. Not approved; no human data for MOTS-c itself.
SemaxNasal ACTH-fragment peptide used in Russia. Not FDA-approved; no FDA-reviewed dosing.
SelankTuftsin-analogue peptide used in Russia. Not FDA-approved and not compoundable in the US.
KPVThree-amino-acid fragment of alpha-MSH studied in animal colitis models. No human dosing data.
IpamorelinGhrelin-receptor agonist. Failed a phase 2 trial; not approved and not compoundable.
CJC-1295Long-acting GHRH analogue. Not approved and not compoundable; no trial of the popular ipamorelin combo.
NAD+ injectionsCoenzyme sold alongside peptides. No approved injection; one small IV pharmacokinetic study.
AOD-9604Growth hormone fragment developed as an obesity pill. Failed phase 2b; development stopped in 2007.
Epitalon (epithalon)Four-amino-acid peptide modeled on a pineal extract. Small, non-randomized studies only; no established dose.
DSIP (delta sleep-inducing peptide)Nine-amino-acid sleep peptide from the 1970s. Mixed IV studies; advisory committee voted against it in 2026.
What changed in 2026
- April: the FDA removed 12 peptides, including BPC-157, TB-500 and GHK-Cu, from its "significant safety risks" compounding list after the nominations were withdrawn. Removal did not make them legal to compound.
- July: an FDA advisory committee voted to recommend six peptides for compounding and rejected DSIP. The votes are not binding.
- October 30: HHS published a draft policy not to act against pharmacies compounding BPC-157, TB-500, MOTS-c, epitalon, KPV and semax under strict conditions.
- Approvals: orforglipron (Foundayo) in April and a higher-dose Wegovy. Retatrutide is still in phase 3, with a filing planned for 2027.
The methodology page explains how statuses and doses are checked.
Questions
- What is a peptide?
- A short chain of amino acids, the same building blocks that make up proteins. Peptides are generally shorter than proteins. Many hormones in the body are peptides, including insulin and GLP-1.
- What are peptide injections?
- Peptides are usually injected under the skin because the stomach breaks most of them down. The term covers two very different things: FDA-approved prescription drugs such as tirzepatide or semaglutide, and unapproved powders sold online as 'research chemicals'.
- What is peptide therapy?
- A marketing term, mostly used by clinics and online sellers, for using peptides such as BPC-157 or ipamorelin for healing, anti-aging or body composition. Most of those peptides are not FDA-approved and have little controlled human evidence.
- Are peptides legal?
- FDA-approved peptide drugs are legal with a prescription. Unapproved peptides cannot be sold for human use; the FDA sent warning letters to 'research use only' sellers in 2026. As of November 2026, HHS has a draft policy that would let state-licensed pharmacies compound six peptides (BPC-157, TB-500, MOTS-c, epitalon, KPV, semax) on prescription. That is not FDA approval.
- Are peptides safe?
- Approved peptide drugs have known risks listed on their labels. For unapproved peptides the honest answer is that nobody knows: there is little human safety data, and products bought online are not checked for purity or dose.
Sources
- FDA: Certain bulk drug substances for compounding that may present significant safety risks
- FDA: 503A bulk drug substance categories (updated May 14, 2026, PDF)
- Federal Register (public inspection) 2026-07361: peptide category changes
- PharmExec: FDA advisory committee votes to loosen restrictions on peptides (Jul 2026)
- Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
- FDA warning letter to TXP Innovations (Tex Peptides), Aug 24, 2026
- Rybelsus (semaglutide tablets) US prescribing information
- Healio: FDA approves orforglipron, an oral GLP-1, for adults with obesity (Apr 2026)
- FDA approves higher-dose semaglutide under the national priority voucher program (Mar 2026)
- Epocrates: Retatrutide heads toward FDA filing after positive phase 3 results
Last checked 2026-11-16. How we pick and check sources: methodology.